Novel value measures and European HTA: Implications for pharma/device HEOR
The term "value" may be thought of as "benefit" which, in turn, triggers a discussion on the opportunity cost of other forgone benefits. New cost-effectiveness modeling methods are required to accommodate the novel sources of value.